MSB 0.51% 97.0¢ mesoblast limited

Cell Therapy News/Articles, page-5259

  1. 603 Posts.
    lightbulb Created with Sketch. 292
    It was a Phase 3 trial.
    The industry press are talking as though this is the end of the IL-6 drugs as a treatment for COVID. Missed the primary endpoint big time, (p-0.36) but achieve some modest reduction in time to discharge (p-.037). But certainly no better than placebo in reducing mortality.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.